BIO-RISE CHINA: A Randomized Trial of a Biolimus-Coated Balloon Versus Plain Old Balloon Angioplasty in Small Vessel Coronary Artery Disease

ClinicalTrials.gov Identifier: NCT03769623

Brief Summary:
This study is a prospective, multicenter, randomized, blind, parallel and superiority test study. It is planned to select 206 cases of subjects with small coronary artery vessel disease who meet the inclusion/exclusion criteria. They are randomly divided into Biolimus A9™ (BA9™) release coronary balloon catheter treatment group and plain old balloon angioplasty catheter (Powerline™) treatment group according to the ratio of 1:1. All subjects accept clinical follow-up after operation, at 30 days, 6 months, 9 months and 12 months after operation. Follow-up with angiography is conducted at 9 months.

Primary end-point:
In-segment late lumen loss (LLL) at 9 months assessed by an independent core-lab blinded to treatment assignment.

Secondary end-points:
- Device and procedural success
- Binary restenosis
- Target lesion failure (TLF) at 30 days, 6, 9 and 12 months
- Patient orientated clinical outcome (POCO) defined as a composite of all-cause death, myocardial infarction and any revascularization at the same time points

Study device:
The Biolimus A9™ DCB is an investigational device and is not yet approved for sales. It features the following caracteristics:
- Balloon: semi-compliant angioplasty balloon
- Coating: 3 µg/mm2 Crystalline Biolimus A9. BA9™ is a highly lipophilic anti-restenotic drug and was specifically developed by Biosensors International for local drug delivery into vascular tissue.
- Excipient: polyethylene oxide (PEO)
- Mechanism of action: Ultra fast direct transfer of the highly lipophilic1 BA9™ to vessel wall on balloon expansion.

Results:
In a Late Breaking Clinical Trials session at TCT2021, Dr. Yaling Han presented the following results:
0.16±0.29mm vs 0.30±0.35mm ∆ 0.14mm; 95% CI -0.23 to -0.05; p=0.001 (per protocol population) and concluded:
- “This first-in-human randomized controlled trial has confirmed the safety and efficacy of a biolimus coated balloon in patients with small vessel coronary artery disease compared to plain old balloon angioplasty;
- Late lumen enlargement was 3 times more common with the biolimus coated balloon;
- There was a trend towards improved clinical outcomes at 1 year;
- Future studies are warranted to compare the BCB to DES and/or other DCBs”.

  

tct21-day3-thumvideo_0.jpg

Biosensors International would like to thank all Patients and Investigators for making this trial possible!


1. Biosensors International data on file.
Sources:
https://www.clinicaltrials.gov.
BIO-RISE CHINA: A Randomized Trial of a Biolimus-Coated Balloon Versus Plain Old Balloon Angioplasty in Small Vessel Coronary Artery Disease. PI: Dr. Yaling Han, Site PI: Dr. Kai Xu, On behalf of the BIO-RISE CHINA Investigators


TCT21b

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J®, RISE™ NC and RISE™ SC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT GmbH. Blue Sail Medical Co., Ltd is the ultimate parent company of NVT GmbH and Biosensors International Group, Ltd. and its subsidiaries are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent, Rise NC and Rise SC are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. All other cited trademarks are the property of their respective owners.